104 results
Page 2 of 6
8-K
EX-99.3
jqn9qpg
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
c7tmrq3jcgsofjlx
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.2
g0agguf3iobv671dcp
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.1
egcytjo 35fzyjuq5do
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-99.2
wqyrg
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-99.1
x7o7k4 5m6lyfmq
26 May 23
Regulation FD Disclosure
12:38pm
8-K
zhsm9d xn6oo40rg
26 May 23
Regulation FD Disclosure
12:38pm
PRE 14A
41tdh445scext
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.2
emjlr9pqhzykt9 6o
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.1
gn0ffvnfgrddvzzebx
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am
8-K
EX-99.2
lg5ecjre toocr8s9
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am
8-K
EX-99.2
rsxcfdtprt3cvwa0
9 Aug 22
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
12:00am
8-K
EX-1.1
4iecjg35ke92r 48
16 May 22
Other Events
5:18pm
424B5
fqcsmn1h
16 May 22
Prospectus supplement for primary offering
5:17pm
8-K
EX-99.1
ywlbee9694uy6q dj7s
5 May 22
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
7:05am